Expression Pattern of Purinergic Signaling Components in Colorectal Cancer Cells and Differential Cellular Outcomes Induced by Extracellular ATP and Adenosine.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 Oct 2021
Historique:
received: 07 10 2021
revised: 19 10 2021
accepted: 20 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 15 12 2021
Statut: epublish

Résumé

The purine nucleotide adenosine triphosphate (ATP) is known for its fundamental role in cellular bioenergetics. However, in the last decades, different works have described emerging functions for ATP, such as that of a danger signaling molecule acting in the extracellular space on both tumor and stromal compartments. Beside its role in immune cell signaling, several studies have shown that high concentrations of extracellular ATP can directly or indirectly act on cancer cells. Accordingly, it has been reported that purinergic receptors are widely expressed in tumor cells. However, their expression pattern is often associated with contradictory cellular outcomes. In this work, we first investigated gene expression profiles through "RNA-Sequencing" (RNA Seq) technology in four colorectal cancer (CRC) cell lines (HT29, LS513, LS174T, HCT116). Our results demonstrate that CRC cells mostly express the A2B, P2X4, P2Y1, P2Y2 and P2Y11 purinergic receptors. Among these, the P2Y1 and P2Y2 coding genes are markedly overexpressed in all CRC cells compared to the HCEC-1CT normal-like colonic cells. We then explored the cellular outcomes induced by extracellular ATP and adenosine. Our results show that in terms of cell death induction extracellular ATP is consistently more active than adenosine against CRC, while neither compound affected normal-like colonic cell survival. Intriguingly, while for the P2Y2 receptor pharmacological inhibition completely abolished the rise in cytoplasmic Ca

Identifiants

pubmed: 34768902
pii: ijms222111472
doi: 10.3390/ijms222111472
pmc: PMC8583864
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Receptors, Purinergic 0
Adenosine Triphosphate 8L70Q75FXE
Adenosine K72T3FS567
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Cancer Res. 2019 Feb 15;25(4):1318-1330
pubmed: 30420446
Cancers (Basel). 2021 Jan 07;13(2):
pubmed: 33430230
Hepatol Res. 2006 Sep;36(1):56-60
pubmed: 16844405
EMBO J. 2006 Nov 1;25(21):5071-82
pubmed: 17036048
Endocrinology. 1998 May;139(5):2382-91
pubmed: 9564849
Thromb Res Suppl. 1983;4:39-46
pubmed: 6356465
Br J Pharmacol. 1970 Dec;40(4):668-88
pubmed: 4322041
J Gastroenterol. 2009;44(1):56-65
pubmed: 19159073
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Oncogene. 2017 Jan 19;36(3):293-303
pubmed: 27321181
Nat Rev Drug Discov. 2019 Oct;18(10):770-796
pubmed: 31388135
Immunol Rev. 1998 Feb;161:95-109
pubmed: 9553767
Stem Cell Rev Rep. 2020 Apr;16(2):288-300
pubmed: 31813120
Br J Clin Pharmacol. 2011 Oct;72(4):634-46
pubmed: 21649691
Purinergic Signal. 2016 Mar;12(1):25-57
pubmed: 26545760
J Exp Clin Cancer Res. 2014 Jun 24;33:53
pubmed: 24961145
PLoS One. 2008 Jul 09;3(7):e2599
pubmed: 18612415
Purinergic Signal. 2019 Sep;15(3):367-374
pubmed: 31401785
J Biol Chem. 2014 Jul 4;289(27):19137-49
pubmed: 24847054
Trends Pharmacol Sci. 2006 Apr;27(4):211-7
pubmed: 16530853
Exp Hematol Oncol. 2020 Nov 24;9(1):32
pubmed: 33292604
Int J Clin Exp Pathol. 2020 Feb 01;13(2):107-121
pubmed: 32211091
Biochem Biophys Res Commun. 1998 Oct 29;251(3):811-7
pubmed: 9790992
Oncogene. 2010 Sep 30;29(39):5346-58
pubmed: 20661219
Genome Biol. 2014;15(12):550
pubmed: 25516281
Hum Pathol. 2017 Jun;64:61-68
pubmed: 28412208
Oncol Rep. 2018 Jan;39(1):138-150
pubmed: 29115551
Br J Cancer. 2013 Sep 17;109(6):1666-75
pubmed: 23969730
Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt B):1786-1794
pubmed: 29842892
Gastroenterology. 2010 Mar;138(3):1012-21.e1-5
pubmed: 19962984
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52
pubmed: 20080644
Cell Physiol Biochem. 2010;26(2):125-34
pubmed: 20798496
Bioinformatics. 2012 Jun 1;28(11):1542-3
pubmed: 22492314
Cancer Lett. 2019 Dec 28;467:58-71
pubmed: 31560934
Acta Pharmacol Sin. 2006 Aug;27(8):1085-92
pubmed: 16867263
Immunity. 2013 Jul 25;39(1):74-88
pubmed: 23890065
Am J Physiol Cell Physiol. 2003 Aug;285(2):C286-99
pubmed: 12660148
Biochem Biophys Res Commun. 1996 Jan 5;218(1):344-51
pubmed: 8573158
J Immunol. 2011 Jul 15;187(2):676-83
pubmed: 21677139
Adv Med Sci. 2019 Sep;64(2):388-394
pubmed: 31276917
Nat Rev Immunol. 2016 Mar;16(3):177-92
pubmed: 26922909
Sci Rep. 2019 Aug 12;9(1):11587
pubmed: 31406126
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2584-602
pubmed: 25450340
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Histopathology. 2004 Mar;44(3):206-15
pubmed: 14987223
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Oral Oncol. 2020 Jun 12;109:104808
pubmed: 32540611
Cell Biosci. 2018 Apr 3;8:25
pubmed: 29636894
Biochem Pharmacol. 2021 May;187:114406
pubmed: 33412103
Biochim Biophys Acta. 2001 Apr 23;1538(2-3):190-205
pubmed: 11336790
Cancers (Basel). 2014 Feb 26;6(1):436-58
pubmed: 24577242
BMC Cancer. 2015 Jul 31;15:563
pubmed: 26228921
Nat Rev Cancer. 2018 Oct;18(10):601-618
pubmed: 30006588
Blood. 2002 Jan 15;99(2):706-8
pubmed: 11781259
Cells. 2020 Jul 03;9(7):
pubmed: 32635260
Auton Neurosci. 2004 May 31;112(1-2):69-79
pubmed: 15233932
Oncotarget. 2017 Jul 25;8(30):48755-48768
pubmed: 28548944
Endocrinology. 2008 Jan;149(1):389-96
pubmed: 17947359
J Cell Biol. 1991 Jan;112(2):279-88
pubmed: 1988462
Oncotarget. 2016 May 10;7(19):28736-47
pubmed: 26908460
Purinergic Signal. 2010 Jun;6(2):211-20
pubmed: 20806013
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cells. 2020 Nov 17;9(11):
pubmed: 33212982
Biochem Pharmacol. 2021 May;187:114361
pubmed: 33309519
Nature. 2009 Sep 10;461(7261):282-6
pubmed: 19741708
Biochem Pharmacol. 2013 Dec 1;86(11):1531-40
pubmed: 24021350
Front Pharmacol. 2020 Jun 04;11:793
pubmed: 32581786
Curr Pharm Des. 2016;22(44):6625-6644
pubmed: 27587198
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Biochim Biophys Acta. 2011 May;1808(5):1400-12
pubmed: 20888788
Oncotarget. 2014 Oct 15;5(19):9322-34
pubmed: 25238333
Vascul Pharmacol. 2008 Apr-Jun;48(4-6):143-9
pubmed: 18342579
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Auton Autacoid Pharmacol. 2007 Apr;27(2):79-84
pubmed: 17391276
Cancer Lett. 2014 Sep 1;351(2):242-51
pubmed: 24973521
Signal Transduct Target Ther. 2021 Jul 12;6(1):263
pubmed: 34248142
Int J Colorectal Dis. 2001 Jun;16(3):154-66
pubmed: 11459289
Oncotarget. 2017 Jan 31;8(5):8854-8866
pubmed: 27750219
Cancer Cell Int. 2019 Oct 1;19:254
pubmed: 31582910
J Biol Chem. 2000 Mar 31;275(13):9390-5
pubmed: 10734083
Adv Exp Med Biol. 2017;1051:91-106
pubmed: 28815512
Asian Pac J Cancer Prev. 2014;15(5):1931-6
pubmed: 24716914
Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G1024-35
pubmed: 15662049
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Purinergic Signal. 2009 Sep;5(3):351-68
pubmed: 19399640
Nature. 2018 Aug;560(7718):325-330
pubmed: 30089904
Biochim Biophys Acta Mol Cell Res. 2017 Jan;1864(1):51-61
pubmed: 27741412
Hum Pathol. 2010 Nov;41(11):1550-7
pubmed: 20619442
BMC Cancer. 2008 Dec 19;8:380
pubmed: 19099561
Anticancer Res. 1991 Mar-Apr;11(2):737-43
pubmed: 2064328
J Invest Dermatol. 2003 Aug;121(2):315-27
pubmed: 12880424
Cold Spring Harb Perspect Biol. 2011 Jan 01;3(1):a004143
pubmed: 21123395
Cancer Lett. 2010 Jul 28;293(2):189-97
pubmed: 20202742
Purinergic Signal. 2019 Dec;15(4):451-463
pubmed: 31478181
Cell Death Dis. 2012 Sep 13;3:e390
pubmed: 22972376
Breast Cancer Res Treat. 2004 Jan;83(1):1-10
pubmed: 14997049
Blood. 2002 Aug 1;100(3):925-32
pubmed: 12130504

Auteurs

Clémentine Dillard (C)

Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France.

Chloé Borde (C)

Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France.

Ammara Mohammad (A)

Genomics Core Facility, Institut de Biologie de l'ENS (IBENS), Département de Biologie, École Normale Supérieure, Université PSL, CNRS, INSERM, F-75005 Paris, France.

Virginie Puchois (V)

Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France.
Alliance for Research in Cancerology-APREC, Tenon Hospital, F-75020 Paris, France.

Laurent Jourdren (L)

Genomics Core Facility, Institut de Biologie de l'ENS (IBENS), Département de Biologie, École Normale Supérieure, Université PSL, CNRS, INSERM, F-75005 Paris, France.

Annette K Larsen (AK)

Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France.

Michèle Sabbah (M)

Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France.

Vincent Maréchal (V)

Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France.

Alexandre E Escargueil (AE)

Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France.

Elodie Pramil (E)

Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France.
Alliance for Research in Cancerology-APREC, Tenon Hospital, F-75020 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH